

Marinos C Dalakas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/990663/publications.pdf>

Version: 2024-02-01

219
papers

22,136
citations

7561

77
h-index

9334

143
g-index

224
all docs

224
docs citations

224
times ranked

12443
citing authors

#	ARTICLE	IF	CITATIONS
1	Polymyositis and dermatomyositis. <i>Lancet, The</i> , 2003, 362, 971-982.	6.3	1,306
2	A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis. <i>New England Journal of Medicine</i> , 1993, 329, 1993-2000.	13.9	1,024
3	A New Approach to the Classification of Idiopathic Inflammatory Myopathy. <i>Medicine (United States)</i> , 1991, 70, 360-374.	0.4	889
4	Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy. <i>New England Journal of Medicine</i> , 1990, 322, 1098-1105.	13.9	849
5	Polymyositis, Dermatomyositis, and Inclusion-Body Myositis. <i>New England Journal of Medicine</i> , 1991, 325, 1487-1498.	13.9	844
6	Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. <i>Lancet Neurology, The</i> , 2008, 7, 136-144.	4.9	582
7	Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Annals of Neurology</i> , 2001, 50, 195-201.	2.8	577
8	Inflammatory Muscle Diseases. <i>New England Journal of Medicine</i> , 2015, 372, 1734-1747.	13.9	559
9	High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome. <i>New England Journal of Medicine</i> , 2001, 345, 1870-1876.	13.9	396
10	A Long-Term Follow-up Study of Patients with Post-Poliomyelitis Neuromuscular Symptoms. <i>New England Journal of Medicine</i> , 1986, 314, 959-963.	13.9	350
11	Controlled Trial of Plasma Exchange and Leukapheresis in Polymyositis and Dermatomyositis. <i>New England Journal of Medicine</i> , 1992, 326, 1380-1384.	13.9	320
12	Chronic relapsing (Dysimmune) polyneuropathy: Pathogenesis and treatment. <i>Annals of Neurology</i> , 1981, 9, 134-145.	2.8	280
13	Placebo-controlled trial of rituximab in IgM anti-“myelin” associated glycoprotein antibody demyelinating neuropathy. <i>Annals of Neurology</i> , 2009, 65, 286-293.	2.8	274
14	Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2367.	3.8	263
15	A Study of the Interferon Antiviral Mechanism: Apoptosis Activation by the 2’5A System. <i>Journal of Experimental Medicine</i> , 1997, 186, 967-972.	4.2	256
16	Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. <i>Journal of Clinical Investigation</i> , 2009, 119, 1806-1813.	3.9	237
17	Neuromuscular diseases associated with human immunodeficiency virus infection. <i>Annals of Neurology</i> , 1988, 23, S38-S48.	2.8	236
18	Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. <i>Journal of Clinical Investigation</i> , 2015, 125, 4160-4170.	3.9	229

#	ARTICLE	IF	CITATIONS
19	Intravenous immunoglobulin in neurologyâ€™mode of action and clinical efficacy. Nature Reviews Neurology, 2015, 11, 80-89.	4.9	228
20	Advances in the diagnosis, pathogenesis and treatment of CIDP. Nature Reviews Neurology, 2011, 7, 507-517.	4.9	218
21	Peripheral neuropathy and antiretroviral drugs. Journal of the Peripheral Nervous System, 2001, 6, 14-20.	1.4	208
22	Intravenous Immune Globulin Therapy for Neurologic Diseases. Annals of Internal Medicine, 1997, 126, 721.	2.0	204
23	Guillain-BarrÃ© syndrome: The first documented COVID-19â€™triggered autoimmune neurologic disease. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	201
24	A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology, 1996, 40, 792-795.	2.8	200
25	Immunopathogenesis of inflammatory myopathies. Annals of Neurology, 1995, 37, 74-86.	2.8	195
26	Polymyositis Associated With AIDS Retrovirus. JAMA - Journal of the American Medical Association, 1986, 256, 2381.	3.8	193
27	Sporadic inclusion body myositisâ€™diagnosis, pathogenesis and therapeutic strategies. Nature Clinical Practice Neurology, 2006, 2, 437-447.	2.7	192
28	The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. , 2004, 102, 177-193.		189
29	Interrelation of inflammation and APP in sIBM: IL-1Î² induces accumulation of Î²-amyloid in skeletal muscle. Brain, 2008, 131, 1228-1240.	3.7	184
30	Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups. Annals of Neurology, 1985, 18, 655-659.	2.8	183
31	Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines. Muscle and Nerve, 1999, 22, 1479-1497.	1.0	183
32	Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain, 2009, 132, 1536-1544.	3.7	182
33	The Stiff-Person Syndrome: An Autoimmune Disorder Affecting Neurotransmission of Î³-Aminobutyric Acid. Annals of Internal Medicine, 1999, 131, 522.	2.0	176
34	Acute axonal Guillain-BarrÃ© syndrome with IgG antibodies against motor axons following parenteral gangliosides. Annals of Neurology, 1995, 38, 218-224.	2.8	166
35	Stiff person syndrome: Advances in pathogenesis and therapeutic interventions. Current Treatment Options in Neurology, 2009, 11, 102-110.	0.7	164
36	Complement in neurological disorders and emerging complement-targeted therapeutics. Nature Reviews Neurology, 2020, 16, 601-617.	4.9	163

#	ARTICLE	IF	CITATIONS
37	B cells as therapeutic targets in autoimmune neurological disorders. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 557-567.	2.7	162
38	Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Neurological Sciences</i> , 1992, 107, 111-121.	0.3	161
39	Immunotherapy of myositis: issues, concerns and future prospects. <i>Nature Reviews Rheumatology</i> , 2010, 6, 129-137.	3.5	151
40	Inflammatory Muscle Diseases. <i>New England Journal of Medicine</i> , 2015, 373, 393-394.	13.9	145
41	Immunocytochemical and virological characteristics of hiv-associated inflammatory myopathies: Similarities with seronegative polymyositis. <i>Annals of Neurology</i> , 1991, 29, 474-481.	2.8	144
42	Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. <i>Brain</i> , 2005, 128, 1887-1896.	3.7	144
43	Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. <i>Neurology</i> , 2002, 59, S13-21.	1.5	139
44	Chronic idiopathic ataxic neuropathy. <i>Annals of Neurology</i> , 1986, 19, 545-554.	2.8	136
45	Neurological complications of immune checkpoint inhibitors: what happens when you “take the brakes off” the immune system. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641879986.	1.5	136
46	Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. <i>Muscle and Nerve</i> , 1988, 11, 1169-1176.	1.0	134
47	Inclusion body myositis in HIV-1 and HTLV-1 infected patients. <i>Brain</i> , 1996, 119, 1887-1893.	3.7	134
48	Analysis of GAD65 Autoantibodies in Stiff-Person Syndrome Patients. <i>Journal of Immunology</i> , 2005, 175, 7755-7762.	0.4	133
49	Î²-Amyloid is a substrate of autophagy in sporadic inclusion body myositis. <i>Annals of Neurology</i> , 2007, 61, 476-483.	2.8	126
50	Immunotherapy in myasthenia gravis in the era of biologics. <i>Nature Reviews Neurology</i> , 2019, 15, 113-124.	4.9	123
51	Drug Insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 36-44.	2.7	121
52	Motor cortex excitability in stiff-person syndrome. <i>Brain</i> , 2000, 123, 2231-2239.	3.7	117
53	Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. <i>Brain</i> , 2006, 129, 3270-3276.	3.7	116
54	Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder. <i>BMC Neurology</i> , 2019, 19, 1.	0.8	112

#	ARTICLE	IF	CITATIONS
55	Expression of the Costimulatory Molecule BB-1, the Ligands CTLA-4 and CD28, and their mRNA in Inflammatory Myopathies. <i>American Journal of Pathology</i> , 1999, 155, 453-460.	1.9	111
56	Downregulation of TGF- β 1 mRNA and Protein in the Muscles of Patients with Inflammatory Myopathies after Treatment with High-Dose Intravenous Immunoglobulin. <i>Clinical Immunology</i> , 2000, 94, 99-104.	1.4	111
57	Pathogenetic Mechanisms of Post-Polio Syndrome: Morphological, Electrophysiological, Virological, and Immunological Correlations. <i>Annals of the New York Academy of Sciences</i> , 1995, 753, 167-185.	1.8	110
58	Anti- γ -Glutamic Acid Decarboxylase Antibodies in the Serum and Cerebrospinal Fluid of Patients With Stiff-Person Syndrome. <i>Archives of Neurology</i> , 2004, 61, 902.	4.9	110
59	Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	110
60	Molecular Immunology and Genetics of Inflammatory Muscle Diseases. <i>Archives of Neurology</i> , 1998, 55, 1509.	4.9	107
61	Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	103
62	Mechanisms of Disease: signaling pathways and immunobiology of inflammatory myopathies. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 219-227.	3.2	101
63	Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. <i>Archives of Neurology</i> , 2010, 67, 802.	4.9	99
64	Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e131.	3.1	98
65	Inflammatory muscle diseases: a critical review on pathogenesis and therapies. <i>Current Opinion in Pharmacology</i> , 2010, 10, 346-352.	1.7	97
66	Dysphagia in Patients with the Post-Polio Syndrome. <i>New England Journal of Medicine</i> , 1991, 324, 1162-1167.	13.9	96
67	Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. <i>Neurology</i> , 2006, 67, 1068-1070.	1.5	95
68	Invited Article: Inhibition of B cell functions. <i>Neurology</i> , 2008, 70, 2252-2260.	1.5	95
69	Sensory neuropathy associated with monoclonal immunoglobulin M to GD1b ganglioside. <i>Annals of Neurology</i> , 1992, 31, 683-685.	2.8	93
70	Inflammatory, immune, and viral aspects of inclusion-body myositis. <i>Neurology</i> , 2006, 66, S33-S38.	1.5	93
71	Pathogenesis of immune-mediated neuropathies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 658-666.	1.8	92
72	Tremor as a Feature of Chronic Relapsing and Dysgammaglobulinemic Polyneuropathies. <i>Archives of Neurology</i> , 1984, 41, 711.	4.9	91

#	ARTICLE	IF	CITATIONS
73	Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. <i>Nature Reviews Neurology</i> , 2015, 11, 143-156.	4.9	91
74	Pathogenesis and therapies of immune-mediated myopathies. <i>Autoimmunity Reviews</i> , 2012, 11, 203-206.	2.5	90
75	MHC Class I-Mediated Cytotoxicity Does Not Induce Apoptosis in Muscle Fibers nor in Inflammatory T Cells. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 1205-1209.	0.9	86
76	Strokes, thromboembolic events, and IVIg. <i>Neurology</i> , 2003, 60, 1736-1737.	1.5	86
77	Cranial neuropathies and COVID-19. <i>Neurology</i> , 2020, 95, 195-196.	1.5	86
78	Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. <i>Brain</i> , 2004, 127, 1182-1190.	3.7	84
79	Incidence and Prevalence of Major Central Nervous System Involvement in Systemic Lupus Erythematosus: A 3-Year Prospective Study of 370 Patients. <i>PLoS ONE</i> , 2013, 8, e55843.	1.1	83
80	Inclusion body myositis with human immunodeficiency virus infection: Four cases with clonal expansion of viral-specific T cells. <i>Annals of Neurology</i> , 2007, 61, 466-475.	2.8	79
81	A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. <i>Annals of Neurology</i> , 2017, 82, 271-277.	2.8	78
82	Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: A controlled study. <i>Journal of the Neurological Sciences</i> , 2014, 347, 143-147.	0.3	76
83	Polymyositis in patients infected with human T-cell leukemia virus type I: The role of the virus in the cause of the disease. <i>Annals of Neurology</i> , 1994, 36, 643-649.	2.8	75
84	Brain γ -Aminobutyric Acid Changes in Stiff-Person Syndrome. <i>Archives of Neurology</i> , 2005, 62, 970-4.	4.9	75
85	Practical considerations on the use of rituximab in autoimmune neurological disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 93-105.	1.5	74
86	Autoimmune ataxic neuropathies (sensory ganglionopathies): Are glycolipids the responsible autoantigens?. <i>Annals of Neurology</i> , 1996, 39, 419-422.	2.8	73
87	Stiff-person syndrome. <i>Current Treatment Options in Neurology</i> , 2003, 5, 79-90.	0.7	73
88	Peripheral neuropathies in Sjogren syndrome: a new reappraisal. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 798-802.	0.9	73
89	Immune mechanisms in chronic inflammatory demyelinating neuropathy. <i>Neurology</i> , 2002, 59, S7-12.	1.5	73
90	The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. <i>Journal of Neurology</i> , 2005, 252, i19-i25.	1.8	72

#	ARTICLE	IF	CITATIONS
91	Expression of IFN- γ -inducible chemokines in inclusion body myositis. <i>Journal of Neuroimmunology</i> , 2003, 141, 125-131.	1.1	69
92	Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628561774664.	1.5	69
93	Pathophysiology of inflammatory and autoimmune myopathies. <i>Presse Medicale</i> , 2011, 40, e237-e247.	0.8	68
94	Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: Present and future prospects. <i>Annals of Neurology</i> , 1995, 37, 2-13.	2.8	67
95	Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases. <i>Muscle and Nerve</i> , 1997, 20, 1102-1107.	1.0	66
96	Efficacy of Intravenous Immunoglobulin in Neurological Diseases. <i>Neurotherapeutics</i> , 2016, 13, 34-46.	2.1	66
97	Pathogenesis and Treatment of Anti-MAG Neuropathy. <i>Current Treatment Options in Neurology</i> , 2010, 12, 71-83.	0.7	62
98	A critical update on the immunopathogenesis of Stiff Person Syndrome. <i>European Journal of Clinical Investigation</i> , 2010, 40, 1018-1025.	1.7	60
99	Therapeutic targets in patients with inflammatory myopathies: Present approaches and a look to the future. <i>Neuromuscular Disorders</i> , 2006, 16, 223-236.	0.3	59
100	Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1 β -induced accumulation of β -amyloid and cell death. <i>Brain</i> , 2012, 135, 1102-1114.	3.7	58
101	Immunology of stiff person syndrome and other GAD-associated neurological disorders. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 1043-1053.	1.3	57
102	Electrophysiologic correlations with clinical outcomes in CIDP. <i>Muscle and Nerve</i> , 2010, 42, 492-497.	1.0	56
103	Treatment of 'permanent' muscle weakness in familial hypokalemic periodic paralysis. <i>Muscle and Nerve</i> , 1983, 6, 182-186.	1.0	55
104	Inclusion body myositis and paraproteinemia: Incidence and immunopathologic correlations. <i>Annals of Neurology</i> , 1997, 41, 100-104.	2.8	55
105	Interplay between inflammation and degeneration: Using inclusion body myositis to study 'neuroinflammation'. <i>Annals of Neurology</i> , 2008, 64, 1-3.	2.8	55
106	Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. <i>Journal of Clinical Investigation</i> , 2012, 122, 1393-1402.	3.9	55
107	A Double-Blind, Placebo-Controlled, Trial of Amantadine for the Treatment, of Fatigue in Patients with the, Post-Polio Syndrome. <i>Annals of the New York Academy of Sciences</i> , 1995, 753, 296-302.	1.8	53
108	A neuropsychological assessment of phobias in patients with stiff person syndrome. <i>Neurology</i> , 2005, 64, 1961-1963.	1.5	53

#	ARTICLE	IF	CITATIONS
109	IVIg in other autoimmune neurological disorders: current status and future prospects. <i>Journal of Neurology</i> , 2008, 255, 12-16.	1.8	52
110	Rimmed vacuoles with β -amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis. <i>Human Pathology</i> , 1998, 29, 1128-1133.	1.1	51
111	The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): A small pilot study. <i>Journal of the Neurological Sciences</i> , 2013, 334, 123-125.	0.3	51
112	Current treatment of the inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 1994, 6, 595-602.	2.0	50
113	Immunotherapy in autoimmune neuromuscular disorders. <i>Lancet Neurology</i> , The, 2003, 2, 22-32.	4.9	50
114	The importance of FcRn in neuro-immunotherapies: From IgG catabolism, <i>FCGRT</i> gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642199738.	1.5	50
115	Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. <i>Neurology</i> , 2013, 81, 1962-1964.	1.5	49
116	Search for HIV proviral DNA and amplified sequences in the muscle biopsies of patients with HIV polymyositis. <i>Muscle and Nerve</i> , 1993, 16, 408-413.	1.0	48
117	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. <i>Lancet Neurology</i> , The, 2018, 17, 689-698.	4.9	48
118	Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. <i>Current Opinion in Neurology</i> , 1999, 12, 403-409.	1.8	48
119	Therapeutic Approaches in Patients with Inflammatory Myopathies. <i>Seminars in Neurology</i> , 2003, 23, 199-206.	0.5	47
120	Advances in the pathogenesis and treatment of patients with stiff person syndrome. <i>Current Neurology and Neuroscience Reports</i> , 2008, 8, 48-55.	2.0	46
121	Immunotherapy of Inflammatory Myopathies: Practical Approach and Future Prospects. <i>Current Treatment Options in Neurology</i> , 2011, 13, 311-323.	0.7	46
122	Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins. <i>Muscle and Nerve</i> , 2007, 35, 196-202.	1.0	45
123	High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome. <i>Biochemical and Biophysical Research Communications</i> , 2008, 366, 1-7.	1.0	45
124	IgG4-Mediated Neurologic Autoimmunities. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	45
125	Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barré syndrome, myasthenia gravis and dermatomyositis. <i>Journal of Neuroimmunology</i> , 1996, 71, 227-229.	1.1	44
126	The immunobiology of autoimmune encephalitides. <i>Journal of Autoimmunity</i> , 2019, 104, 102339.	3.0	44

#	ARTICLE	IF	CITATIONS
127	Gene expression profiling in chronic inflammatory demyelinating polyneuropathy. <i>Journal of Neuroimmunology</i> , 2005, 159, 203-214.	1.1	43
128	A Double-Blind, Placebo-Controlled Trial of High-Dose Prednisone for the Treatment of Post-Poliomyelitis Syndrome. <i>Annals of the New York Academy of Sciences</i> , 1995, 753, 303-313.	1.8	42
129	Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. <i>Muscle and Nerve</i> , 2009, 39, 448-455.	1.0	42
130	GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders. <i>Journal of Neuroimmunology</i> , 2015, 281, 73-77.	1.1	42
131	B cells in the pathophysiology of autoimmune neurological disorders: A credible therapeutic target. , 2006, 112, 57-70.		40
132	Inflammatory myopathies. <i>Current Opinion in Neurology</i> , 2011, 24, 457-462.	1.8	40
133	Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. <i>Current Opinion in Neurology</i> , 2020, 33, 545-552.	1.8	40
134	Novel future therapeutic options in Myasthenia Gravis. <i>Autoimmunity Reviews</i> , 2013, 12, 936-941.	2.5	39
135	GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110034.	1.5	39
136	Mechanistic Effects of IVIg in Neuroinflammatory Diseases: Conclusions Based on Clinicopathologic Correlations. <i>Journal of Clinical Immunology</i> , 2014, 34, 120-126.	2.0	38
137	Common variable immunodeficiency and inclusion body myositis: A distinct myopathy mediated by natural killer cells. <i>Annals of Neurology</i> , 1995, 37, 806-810.	2.8	37
138	Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2021, 12, 627285.	2.2	37
139	Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. <i>Journal of Neurology</i> , 2011, 258, 1568-1570.	1.8	36
140	Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy. <i>Neurotherapeutics</i> , 2021, 18, 2397-2418.	2.1	36
141	Postherpes simplex encephalitis: a case series of viral-triggered autoimmunity, synaptic autoantibodies and response to therapy. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641876877.	1.5	33
142	Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies. <i>Neurotherapeutics</i> , 2022, 19, 832-847.	2.1	33
143	Future perspectives in target-specific immunotherapies of myasthenia gravis. <i>Therapeutic Advances in Neurological Disorders</i> , 2015, 8, 316-327.	1.5	32
144	HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis. <i>Experimental Neurology</i> , 2015, 271, 189-197.	2.0	32

#	ARTICLE	IF	CITATIONS
145	Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. <i>Journal of Neuroimmunology</i> , 2015, 289, 8-11.	1.1	30
146	Progress and stiff challenges in understanding the role of GAD-antibodies in stiff-person syndrome. <i>Experimental Neurology</i> , 2013, 247, 303-307.	2.0	28
147	Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 1125-1133.	1.3	27
148	Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies. <i>Journal of the Peripheral Nervous System</i> , 2012, 17, 34-39.	1.4	26
149	Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: Quantitative assessment of inflammation and β -amyloid in the muscle. <i>Arthritis and Rheumatism</i> , 2012, 64, 4094-4103.	6.7	25
150	Pathophysiology of autoimmune polyneuropathies. <i>Presse Medicale</i> , 2013, 42, e181-e192.	0.8	25
151	Autoimmune encephalitis with GABA _B antibodies, thymoma, and GABA _B receptor thymic expression. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e39.	3.1	25
152	Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials. <i>Neurotherapeutics</i> , 2016, 13, 20-33.	2.1	25
153	Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. <i>Acta Myologica</i> , 2020, 39, 289-301.	1.5	25
154	Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 691-701.	1.3	25
155	Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. <i>Expert Opinion on Medical Diagnostics</i> , 2010, 4, 241-250.	1.6	23
156	Blockade of blocking antibodies in Guillain-Barré½ syndromes: ?Unblocking? the mystery of action of intravenous immunoglobulin. <i>Annals of Neurology</i> , 2002, 51, 667-669.	2.8	22
157	Immunotherapy-responsive limbic encephalitis with antibodies to glutamic acid decarboxylase. <i>Journal of the Neurological Sciences</i> , 2014, 343, 192-194.	0.3	22
158	Are autoantibodies pathogenic in necrotizing myopathy?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 251-252.	3.5	22
159	Potential biomarkers for monitoring therapeutic response in patients with CIDP. <i>Journal of the Peripheral Nervous System</i> , 2011, 16, 63-67.	1.4	21
160	Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases. <i>Neurotherapeutics</i> , 2022, 19, 691-710.	2.1	21
161	Basic Principles of Immunotherapy for Neurologic Diseases. <i>Seminars in Neurology</i> , 2003, 23, 121-132.	0.5	20
162	Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e460.	3.1	20

#	ARTICLE	IF	CITATIONS
163	Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1037-1037.	0.9	18
164	Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM. <i>BMC Neurology</i> , 2016, 16, 48.	0.8	18
165	Anti-Neuronal Antibodies Within the IVIg Preparations: Importance in Clinical Practice. <i>Neurotherapeutics</i> , 2020, 17, 235-242.	2.1	18
166	Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future. <i>Annals of the New York Academy of Sciences</i> , 2012, 1274, 1-8.	1.8	17
167	Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. <i>Neurotherapeutics</i> , 2016, 13, 163-178.	2.1	17
168	Trial of canakinumab, an IL-1 β receptor antagonist, in patients with inclusion body myositis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, e581.	3.1	17
169	Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 413-423.	1.3	17
170	Progression of Oral-Motor and Swallowing Symptoms in the Post-Polio Syndrome. <i>Annals of the New York Academy of Sciences</i> , 1995, 753, 87-95.	1.8	16
171	Intravenous Immunoglobulin in Patients With Anti-GAD Antibody-Associated Neurological Diseases and Patients With Inflammatory Myopathies: Effects on Clinicopathological Features and Immunoregulatory Genes. <i>Clinical Reviews in Allergy and Immunology</i> , 2005, 29, 255-270.	2.9	16
172	Enteroviruses and Human Neuromuscular Diseases. , 0, , 387-398.		16
173	Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies. <i>Neurotherapeutics</i> , 2022, 19, 741-752.	2.1	16
174	The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. <i>Neurotherapeutics</i> , 2022, 19, 864-873.	2.1	16
175	Gene therapy for Duchenne muscular dystrophy: balancing good science, marginal efficacy, high emotions and excessive cost. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 293-296.	1.5	15
176	Review: Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. <i>Therapeutic Advances in Neurological Disorders</i> , 2008, 1, 157-166.	1.5	13
177	Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 69-73.	1.5	13
178	Reply: Meningitis and Skin Reaction after Intravenous Immune Globulin Therapy. <i>Annals of Internal Medicine</i> , 1997, 127, 1130.	2.0	13
179	Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody-Positive Stiff-Person Syndrome. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	13
180	Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factors. <i>Journal of the Neurological Sciences</i> , 2017, 377, 224-226.	0.3	12

#	ARTICLE	IF	CITATIONS
181	Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece. <i>Clinical Immunology</i> , 2020, 221, 108619.	1.4	12
182	Treatment for inclusion body myositis. <i>The Cochrane Library</i> , 0, , .	1.5	11
183	IVIg efficacy in CIDP patients is not associated with terminal complement inhibition. <i>Journal of Neuroimmunology</i> , 2019, 330, 23-27.	1.1	11
184	Neuroimmunotherapy: A Practical Approach to the Treatment of Immune-Mediated Neurologic Diseases. <i>Seminars in Neurology</i> , 1994, 14, 97-105.	0.5	10
185	Role of the Muscle in Acute Poliomyelitis Infection. <i>Annals of the New York Academy of Sciences</i> , 1995, 753, 58-67.	1.8	10
186	Inflammatory myopathies. , 2010, , 427-452.		9
187	Reliability of the Adult Myopathy Assessment Tool in Individuals With Myositis. <i>Arthritis Care and Research</i> , 2015, 67, 563-570.	1.5	9
188	Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e306.	3.1	9
189	Autoimmune Neurogenic Dysphagia. <i>Dysphagia</i> , 2022, 37, 473-487.	1.0	9
190	Inclusion-body myositis in the elderly: an update. <i>Aging Health</i> , 2010, 6, 687-694.	0.3	8
191	Viruses in IBM. <i>Neurology</i> , 2016, 86, 204-205.	1.5	8
192	Limited Benefits Halt Enrollment in Hematopoietic Stem Cell Transplantation Trial for Stiff-Person Syndrome. <i>Neurology</i> , 2021, 96, 239-240.	1.5	8
193	Aseptic Meningitis and Intravenous Immunoglobulin Therapy. <i>Annals of Internal Medicine</i> , 1995, 122, 316.	2.0	8
194	Identification of macrophages in the muscle biopsy preparations: A comparative study using specific monoclonal antimacrophage antibodies and acid phosphatase reaction. <i>Muscle and Nerve</i> , 1995, 18, 242-244.	1.0	7
195	IVIg in the chronic management of myasthenia gravis: Is it enough for your money?. <i>Journal of the Neurological Sciences</i> , 2014, 338, 1-2.	0.3	7
196	Close to the node but far enough. <i>Neurology</i> , 2016, 86, 796-797.	1.5	7
197	Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future. <i>Neurotherapeutics</i> , 2016, 13, 1-3.	2.1	7
198	Treating myasthenia on consensus guide: Helpful and challenging but still unfinished business. <i>Neurology</i> , 2016, 87, 350-351.	1.5	6

#	ARTICLE	IF	CITATIONS
199	Case 22-2019: A 65-Year-Old Woman with Myopathy. <i>New England Journal of Medicine</i> , 2019, 381, 1693-1694.	13.9	6
200	Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data. <i>Neurological Sciences</i> , 2022, 43, 2641-2649.	0.9	6
201	Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4. <i>Autoimmunity</i> , 2015, 48, 453-9.	1.2	6
202	How To Design a Therapeutic Study in Patients with the Post-Polio Syndrome.. <i>Annals of the New York Academy of Sciences</i> , 1995, 753, 314-320.	1.8	5
203	Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. <i>Lancet Neurology</i> , The, 2018, 17, 20-21.	4.9	5
204	Autoimmune peripheral neuropathies. , 2008, , 977-994.		4
205	Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	4
206	N2 year in review. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e925.	3.1	3
207	Unconvincing Evidence of SARS-CoV-2â€œAssociated Myositis in Autopsied Muscles. <i>JAMA Neurology</i> , 2022, 79, 92.	4.5	3
208	Natalizumab therapy in patients with pediatric-onset multiple sclerosis in Greece: clinical and immunological insights of time-long administration and future directionsâ€œa single-center retrospective observational study. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 933-943.	1.4	3
209	Use of Intravenous Immunoglobulin in Neurology. , 2018, , 101-109.		2
210	Treatment of Stiff-Person Syndrome. <i>Current Clinical Neurology</i> , 2019, , 333-335.	0.1	2
211	Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 313-318.	1.4	2
212	Autoimmune Peripheral Neuropathies. , 2019, , 903-915.e1.		1
213	N2 year in review. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e644.	3.1	1
214	LG11 encephalitis with squamous lung-cell carcinoma: Resolution after tumor resection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	1
215	Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies. <i>Neurotherapeutics</i> , 2022, 19, 687-690.	2.1	1
216	PolioRedux. <i>The Sciences</i> , 1995, 35, 30-35.	0.1	0

#	ARTICLE	IF	CITATIONS
217	Concluding Remarks and Future Strategies. <i>Annals of the New York Academy of Sciences</i> , 1995, 753, 366-369.	1.8	0
218	Autoimmune peripheral neuropathies. , 2013, , 801-811.		0
219	Progressive multifocal fibrosing neuropathy: description of a novel disease. <i>Acta Neuropathologica Communications</i> , 2022, 10, 34.	2.4	0